Submission Details
| 510(k) Number | K223293 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | October 26, 2022 |
| Decision Date | November 18, 2022 |
| Days to Decision | 23 days |
| Submission Type | Special |
| Review Panel | Chemistry (CH) |
| Summary | Summary PDF |
K223293 is an FDA 510(k) clearance for the CONTOUR? NEXT GEN Blood Glucose Monitoring System, a System, Test, Blood Glucose, Over The Counter (Class II — Special Controls, product code NBW), submitted by Ascensia Diabetes Care U.S., Inc. (Valhalla, US). The FDA issued a Cleared decision on November 18, 2022, 23 days after receiving the submission on October 26, 2022. This device falls under the Chemistry review panel. Regulated under 21 CFR 862.1345.
| 510(k) Number | K223293 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | October 26, 2022 |
| Decision Date | November 18, 2022 |
| Days to Decision | 23 days |
| Submission Type | Special |
| Review Panel | Chemistry (CH) |
| Summary | Summary PDF |
| Product Code | NBW — System, Test, Blood Glucose, Over The Counter |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 862.1345 |